John Babcook
25Patents
7h-index
64Co-inventors
72Inventor score
Filing activity: Dec 2, 2002 → Feb 21, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8779108B2 | Targeted binding agents against B7-H1 | Chemistry; Metallurgy | 161 | Active |
| US7285269B2 | Antibodies directed to tumor necrosis factor | Chemistry; Metallurgy | 68 | Expired |
| US8604174B2 | High affinity fully human monoclonal antibodies to interleukin-8 | Chemistry; Metallurgy | 25 | Active |
| US7968684B2 | IL-18 binding proteins | Chemistry; Metallurgy | 21 | Expired |
| US9522876B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | Emerging Cross-Sectional Technologies | 18 | Active |
| US7265212B2 | Anti-CD45RB antibodies | Chemistry; Metallurgy | 15 | Expired |
| US8785600B2 | Anti-GCC antibody molecules and related compositions and methods | Chemistry; Metallurgy | 7 | Active |
| US9926378B2 | Antibodies that bind OV064 and methods of use therefor | Physics | 4 | Active |
| US8759490B2 | Antibodies that bind OV064 and methods of use therefor | Physics | 4 | Active |
| US9421277B2 | Antibodies that bind OV064 and methods of use therefor | Physics | 4 | Active |
| US8323645B2 | Antibodies that bind OV064 and methods of use therefor | Chemistry; Metallurgy | 4 | Active |
| US10201614B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | Emerging Cross-Sectional Technologies | 3 | Active |
| US7728110B2 | Antibodies to SARS coronavirus | Chemistry; Metallurgy | 3 | Active |
| US7754433B2 | Identification of high affinity molecules by limited dilution screening | Physics | 3 | Expired |
| US8101178B2 | Antibodies directed to tumor necrosis factor and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US11208497B2 | Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US8431130B2 | IL-18 binding proteins | Chemistry; Metallurgy | 1 | Active |
| US11090383B2 | Anti-podocalyxin antibodies and methods of using the same | Chemistry; Metallurgy | 1 | Active |
| US11390673B2 | Anti-podocalyxin antibodies and methods of using the same | Chemistry; Metallurgy | 1 | Active |
| US10517958B2 | Compositions and methods for the treatment of platinum-drug resistant cancer | Human Necessities | 0 | Active |
| US12053524B2 | Anti-podocalyxin antibodies and methods of using the same | Chemistry; Metallurgy | 0 | Active |
| US10941211B2 | Anti-GCC antibody molecules and related compositions and methods | Chemistry; Metallurgy | 0 | Active |
| US11617777B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | Emerging Cross-Sectional Technologies | 0 | Active |
| US10675355B2 | VAR2CSA-drug conjugates | Emerging Cross-Sectional Technologies | 0 | Active |
| US12303544B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.